(Sharecast News) - Pharmaceutical services company Open Orphan's hVIVO subsidiary has entered into an exclusive contract with Quotient to support Covid-19 antibody testing in the UK.
Open Orphan said on Monday that hVIVO would use Quotient's MosaiQ Covid-19 antibody microarray to screen for SARS-CoV-2 antibodies.
The AIM-listed group highlighted that the technology had been shown to be 100% effective in detecting Covid-19 antibodies and was able to rule out the presence of them in 98.8% of cases.
Chairman Cathal Friel said: "There is a clear demand for Covid-19 antibody testing and we will be making testing available both as a standalone offering and will also utilise the testing capability to screen volunteers for our industry-leading range of human challenge studies to ensure no disruption to our clients."
In a separate announcement, Open Orphan revealed that it had appointed finnCap as its new joint-broker.
As of 0900 BST, Open Orphan shares had shot up 23.40% to 13.08p.
15 Nov 2021 11:32
Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client
(Sharecast News) - Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.
Read more